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Events at 1 Year
BES EES
P-value(n¼3412) (n¼2530)
All-cause death 2.0% (68) 2.0% (50) 1.0
Cardiac death 1.1% (39) 1.0% (26) 0.71
Myocardial infarction 3.1% (104) 2.9% (73) 0.76
Target lesion revascularization (All) 3.4% (115) 3.5% (88) 0.83
Target lesion revascularization (CD) 2.5% (84) 2.5% (63) 1.0
Target vessel revascularization (All) 5.0% (172) 5.0% (127) 1.0
Target vessel revascularization (CD) 3.6% (122) 3.8% (97) 0.63
Stent thrombosis (deﬁnite) 0.5% (17) 0.2% (5) 0.08
Stent thrombosis (deﬁnite / probable) 0.5% (18) 0.4% (10) 0.57
Target vessel failure 6.4% (219) 6.7% (169) 0.71
Diabetic Patients Non-Diabetic Patients
Events at 5 years
EES
(n¼153)
PES
(n¼172)
p-
value
EES
(n¼744)
PES
(n¼730)
p-
value
Death 15.7% (24) 14.5% (25) 0.77 7.7% (57) 9.3% (68) 0.25
Myocardial Infarction 9.2% (14) 13.4% (23) 0.23 6.6% (49) 11.1% (81) <0.01
Target Vessel
Revascularization
9.2% (14) 15.7% (27) 0.08 7.0% (52) 10.4% (76) 0.02
Target Lesion
Revascularization
7.2% (11) 11.0% (19) 0.23 6.0% (45) 9.2% (67) 0.02
Def./Prob. Stent
Thrombosis
5.9% (9) 7.6% (13) 0.55 2.6% (19) 5.5% (40) <0.01
MACE (Primary
Endpoint)
24.8% (38) 34.3% (59) 0.06 17.1% (127) 23.0% (168) <0.01
SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PM www.jacctctabstracts2014.comConclusions: At 5-years EES was superior with regards to efﬁcacy and safety to
PES in non-diabetic patients. In diabetic patients a late trend towards reduction of
MACE was observed with EES compared to PES, mainly driven by a lower rate
of TVR.
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Background: We sought to investigate the long-term outcomes of an abluminal
groove-ﬁlled biodegradable polymer sirolimus-eluting stent FIREHAWK (MicroPort
Medical, Shanghai, China) compared to an everolimus-eluting stent (EES) XIENCE V
in the randomized TARGET I trial.
Methods: A total of 458 patients with single de novo native coronary lesions < ¼24
mm in length and a coronary artery >¼2.25 to < ¼4.0 mm in diameter were enrolled
in the TARGET I study, a prospective, randomized, non-inferiority trial. The primary
endpoint was in-stent late lumen loss (LLL) at 9-month follow-up. The secondary
endpoint, target lesion failure (TLF), was deﬁned as the composite of cardiac death,
target vessel myocardial infarction (TV-MI), and ischemia-driven target lesion
revascularization (iTLR). Clinical follow-up was scheduled at 1-, 6- and 12-month,
and annually up to 5 years for all enrolled patients. All adverse clinical events were
adjudicated by an independent committee.
Results: Previously reported results demonstrated FIREHAWK stent was non-inferior
to XIENCE V EES for the primary endpoint of 9-month in-stent LLL (0.130.24 mm
vs. 0.130.18 mm, p¼0.94; difference and 95% conﬁdence interval 0.00 [-0.04,
0.04] mm; p for non-inferiority < 0.0001), and had a comparable clinical outcome at
2 years. There were still no signiﬁcant differences between the two groups up to 3
years, and no deﬁnite/probable stent thrombosis occurred in FIREHAWK group.
(Table)Table. Clinical Outcomes through 3 Years
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Clinical Follow-Up, % (n/N) 99.6
(226/
227)
100
(231/
231)
0.50 99.6
(226/
227)
100
(231/
231)
0.50 97.4
(221/
227)
98.7
(228/
231)
0.34
Death, % (n) 0.4 (1) 0.9 (2) 1.00 0.4 (1) 0.9 (2) 1.00 1.8 (4) 1.8 (4) 1.00
Cardiac Death 0.4 (1) 0 (0) 1.00 0.4 (1) 0 (0) 1.00 0.9 (2) 0.4 (1) 0.62
Myocardial Infarction, % (n) 1.3 (3) 2.2 (5) 0.72 1.3 (3) 2.6 (6) 0.50 1.4 (3) 3.1 (7) 0.34
Q Wave MI 0 (0) 0 (0) - 0 (0) 0 (0) - 0.0 (0) 0.4 (1) 1.00
Non Q Wave MI 1.3 (3) 2.2 (5) 0.72 1.3 (3) 2.6 (6) 0.50 1.4 (3) 2.6 (6) 0.50
TV-MI 1.3 (3) 1.7 (4) 1.00 1.3 (3) 1.7 (4) 1.00 1.4 (3) 2.2 (5) 0.72
iTLR, % (n) 0.4 (1) 0.4 (1) 1.00 0.9 (2) 0.9 (2) 1.00 1.8 (4) 1.3 (3) 0.75
Any Revascularization, % (n) 1.8 (4) 4.8 (11) 0.07 2.2 (5) 6.1 (14) 0.04 4.5 (10) 7.5 (17) 0.19
TLF, % (n) 2.2 (5) 2.2 (5) 1.00 2.7 (6) 2.6 (6) 0.97 4.1 (9) 3.5 (8) 0.75
PoCE (composite of all cause death,
all MI, and any revascularization), % (n)
3.5 (8) 7.4 (17) 0.07 4.0 (9) 8.7 (20) 0.04 7.2 (16) 11.0 (25) 0.17
Deﬁnite/Probable Stent Thrombosis, %
(n)
0 (0) 0 (0) - 0 (0) 0 (0) - 0.0 (0) 0.4 (1) 1.00
B172 JACC Vol 64/11/Suppl B j SeptemberConclusions: In the multicenter randomized TARGET I trial, the 3-year follow-up
results conﬁrmed that the novel FIREHAWK stent had a durable safety and efﬁcacy
proﬁle, which was comparable to the XIENCE V EES for the treatment of single de
novo native coronary lesions. (ClinicalTrials.gov Identiﬁer: NCT01196819)
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Background: Drug-eluting stents with biodegradable polymers have been developed
to reduce the risk of very late adverse events. Distinct studies have indicated non-
inferiority of the biodegradable polymer-coated biolimus-eluting stent (Nobori;
BES) compared to the durable polymer-coated everolimus-eluting stent (Xience or
Promus; EES) with regards to safety and efﬁcacy at 1 year. However, these trials
were not powered to detect differences in low-frequency events.
Methods: The all-comers COMPARE II and NEXT clinical trials randomly assigned
5942 patients to BES or EES and is at present the largest pooled analysis of BES in
all-comers requiring percutaneous coronary intervention (PCI). The pre-speciﬁed
composite endpoint was target vessel failure (TVF) deﬁned as cardiac death, target
vessel related myocardial infarction (MI), or clinical-indicated target vessel revascu-
larization (TVR-CD).
Results: The pooled unadjusted 1-year clinical outcomes of the 5942 study patients
(8094 lesions) are tabulated. Covariate adjusted analyses accounting for baseline im-
balances between trials conﬁrmed non-signiﬁcant differences between stent type and
clinical outcomes. The trend for a higher deﬁnite stent thrombosis rate in the BES group
was by multivariate analysis less prominent (HR 2.05 [CI95% 0.75-5.60]; p¼0.16).Conclusions: At 1-year the biodegradable polymer-coated BES has similar safety and
efﬁcacy outcomes as the durable polymer-coated EES. Longer follow-up data is
needed to determine the role of biodegradable polymer-coated BES in real world
clinical practice.
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Background: These are the ﬁrst long-term randomized adjudicated trial data of ﬁve
year results of the Genous bio-engineered endothelial progenitor cell capturing stent
(OrbusNeich BV, Fort Lauderdale, FL, USA) compared with a paclitaxel-eluting
stent(PES).
Methods: In this prospective randomized trial, patients with de-novo coronary artery
lesions carrying a high risk of restenosis (chronic total occlusion,lesion length >
23mm,vessel diameter < 2.8mm or any lesion in a diabetic patient) were randomized
1:1 to the Genous or a PES. The current primary endpoint is adjudicated target vessel
failure (TVF) at 5-years, a composite of cardiac death, myocardial infarction (MI) and
target vessel revascularization. Clinical event rates were estimated by Kaplan-Meier
method and compared with a log-rank test.
Results: A total of 193 patients were included with complete follow-up in 97% of the
subjects. The primary endpoint of TVF was similar at 5 years with Genous 23.8% vs13–17, 2014 j TCT Abstracts/Stents - Drug-eluting: Randomized Trials
Table 1. Angiographic, IVUS and Clinical Results
DESyne Endeavor p-value
Angiographic Results
www.jacctctabstracts2014.com SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PMPES 29.5% (p¼0.55, ﬁg 1a). The event rate between 2 and 5 years was lower in
Genous 4.1% vs PES 17.2%(p¼0.011, ﬁg 1b). The composite of death and MI was
6.3% in Genous vs 12.0% in PES (p¼0.19). Deﬁnite stent thrombosis was observed in
4 cases in PES versus non in Genous.Baseline RVD (post-procedure) 2.840.43 2.910.38 0.2
9-month angiographic/IVUS
In-stent Late Lumen Loss 0.110.32 0.630.42 < 0.001
% neointimal volume 4.55.1 20.911.3 <0.001
Clinical Results
12-month DoCE (%) 4.3 7 0.51
Clinically-indicated TLR 1.4 5.6 0.18
24-month DoCE (%) 4.3 9 0.14
Clinically-indicated TLR 1.4 7 0.04
36-month DoCE (%) 5 12.7 0.057
Clinically-indicated TLR 1.4 9.9 0.008
48-month DoCE (%) 6.5 12.7 0.19
Clinically-indicated TLR 2.2 8.5 0.06Conclusions: The ﬁrst randomized and adjudicated long-term results of the Genous
versus a PES at 5 years show comparable performance and safety. Between two and
ﬁve years a signiﬁcant higher event rate was observed in the PES group compared
with the Genous group. Importantly, no deﬁnite stent thrombosis was observed in the
Genous treated group, compared with four cases in the PES group.
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Background: Evaluate the long-term safety and effectiveness of the Elixir DESyne
Novolimus-Eluting Coronary Stent System (CSS) compared to the Endeavor Zotar-
olimus-Eluting CSS (Medtronic, Santa Rosa, CA) through assessment of clinical,
angiographic, and IVUS endpoints through 5 years.
Methods: 210 patients were randomized 2:1 either to the DESyne CSS loaded with
5 mcg/mm of stent length of Novolimus, a sirolimus metabolite, eluted via a durable
methacrylate polymer, or to the Endeavor CSS loaded with 10 mcg/mm of stent
length of Zotarolimus eluted via a durable phosphoryl choline polymer. All patients
were analyzed for the primary endpoint of late lumen loss (LLL) assessed by QCA
at 9 months. All patients also underwent evaluation for secondary endpoints, which
included a device-orientated composite endpoint (DoCE) deﬁned as: cardiac death;
target vessel MI; clinically-indicated target lesion revascularization (TLR); clini-
cally-indicated target vessel revascularization (TVR); and stent thrombosis all
evaluated at 1, 6, 9, and 12 months and annually through 5 years. In-stent and in-
segment LLL were assessed at 9 months. A subset of patients underwent IVUS
evaluation 9 months.
Results: The study met the non-inferiority endpoint and also demonstrated superiority
of the DESyne CSS as compared to control. Table 1 summarizes angiographic, IVUS,
and clinical results through 4 years.JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/SteConclusions: The DESyne CSS met the non-inferiority endpoint and also demon-
strated superiority as compared to Endeavor at 9 months. Clinical results through 4
years demonstrated lower DoCE (6.5 and 12.7, p¼0.19) and signiﬁcantly lower
clinically-indicated TLR (2.2 and 8.5 p¼0.06) for DESyne vs Endeavor. Final clinical
results through 5 years will be presented.
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Background: US guidelines recommend 12 months of uninterrupted DAPT after
implantation of DES. Prolonged and more powerful DAPT regimens have offered
beneﬁt by reducing VLST, but at the cost of increased risk of bleeding. There is an
emerging need for new stents that are less dependent on prolonged DAPT. The
BioFreedom stent (BFD) releases Biolimus A9, without using a polymer or
binder. Based on an animal model, 98% of the drug diffuses to the vessel wall
within 1 month, leaving a BMS in place. This is generating the hypothesis that BFD
can be associated with a need for shorter DAPT and safety advantage compared
to a polymer based DES. This First-In-Man trial aims to demonstrate the safety
and effectiveness of the BFD compared to the Taxus Liberté pactilaxel-eluting
stent (PES).
Methods: BioFreedom FIM is a prospective, multi-center, randomized trial. 182
patients were enrolled and randomized to BFD Standard Dose (SD, 15.6 mg/mm), or
BFD Low Dose (LD, 7.8 mg/mm), or Taxus Liberté DES. The primary endpoint was
in-stent Late Loss (LL) at 12 months. The main secondary endpoints are IVUS
neointimal volume at 4 & 12 months; MACE (death, MI, emergent bypass or clini-
cally-driven TLR) and ST rates (ARC deﬁned) at 30 days, 4 and 12 months, and then
yearly up to 5 years.
Results: The in-stent LL was non inferior in BFD SD (p non-inf ¼ 0.001) and
trended towards superiority with medians of 0.17mm [0.09, 0.39] vs. 0.35mm
[0.22, 0.57] compared to PES (p sup¼0.11) at 12 months. At 4 years, the clinical
FU was 93.5%. The BFD SD and PES showed similar rates of MACE (BFD SD
13.6% vs. PES 13.3%, p¼1.02) with no deﬁnite/probable ST in any groups.
Interestingly, at 2 years, there was a signiﬁcant difference in adherence to DAPT
between the groups (BFD SD 5.2% vs. PES 18.6%, p¼0.025) which disappeared at
further follow-ups.
Conclusions: The safety and efﬁcacy of the polymer free BioFreedom has been
shown out to 4 years. A large randomized clinical trial (LEADERS FREE) is
currently studying the possibility of using this stent in patients with high
bleeding risk, unable to tolerate a prolonged course of DAPT. The 5-year ﬁnal
results of BioFreedom FIM will be reported for the 1st time during this
presentation.nts - Drug-eluting: Randomized Trials B173
